John Theurer Cancer Center
| John Theurer Cancer Center | |
|---|---|
| Geography | |
| Location | 92 2nd Street, Hackensack, New Jersey, United States |
| Organization | |
| Funding | Non-profit hospital |
| Type | Cancer treatment |
| Affiliated university | Hackensack University Medical Center
Georgetown Lombardi Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center |
| Network | Hackensack Meridian Health |
| Links | |
| Lists | Hospitals in the United States |
John Theurer Cancer Center (JTCC) at the Hackensack University Medical Center (HUMC), and part of the Hackensack Meridian Health (HMH), specializes in oncology services and treatments.[1] It is known for being the first site approved to use cell-based gene therapy to treat patients with certain types of large B-cell lymphoma who have not responded or relapsed after at least two other kinds of treatment; it initiated the first CAR T-cell therapy clinical trials and is a member of the NCI-approved Georgetown Lombardi Comprehensive Cancer Center. Other areas of concentration include bone marrow transplants, stem cell transplantation, lymphoma, leukemia, multiple myeloma, neuro-oncology, cutaneous malignancy, gastrointestinal, geriatric, head and neck, thoracic, urologic, breast, and gynecologic.[2] As of 2023, Andre Goy is chair and Chief Physician Officer.[3][4][5]
Georgetown Lombardi Comprehensive Cancer Center affiliation[edit]
In 2019, JTCC received approval from the National Cancer Institute (NCI) as a member of the NCI-approved Georgetown Lombardi Comprehensive Cancer Center.[6] The partnership focuses on advancing research and treatment in breast cancer, cancer prevention and control, experimental therapeutics and molecular oncology.[7][8][9] The Georgetown Lombardi Comprehensive Center is designated by the National Cancer Institute as a leader in cancer treatment.[10]
Hackensack University Medical Center and Hackensack Meridian Health affiliations[edit]
JTCC is part of Hackensack University Medical Center. HUMC and part of the Hackensack Meridian Health network, which includes Joseph M. Sanzari Children's Hospital, the Cancer Center, a branch of The Betty Torricelli Institute for Breast Care, Ocean Medical Center, Pascack Valley Medical Center, and the Riverview Medical Center.[11][12][13]
In 2022, JTCC expanded its program to Hackensack Meridian Jersey Shore University Medical Center's HOPE Tower, providing access to specialized cancer services and access to clinical trials.[14]
Other affiliations[edit]
JTCC has a partnership with Memorial Sloan Kettering Cancer Center (MSK) to provide cancer care and develop joint standards of care through the oversight of a governing board composed of members from both MSK and HMH.[15]
In 2021, JTCC entered into a clinical affiliation with Regional Cancer Care Associates (RCCA) to open a practice called Toms River Regional Cancer Center in Toms River, NJ. The center provides comprehensive medical and surgical oncology/hematology consultative services by community-based, regional, and national specialists for various types and stages of cancer and serious blood disorders.[13]
In 2022, JTCC entered into a clinical affiliation with St. Joseph's Health to provide expanded cancer care services to the residents of Wayne, Paterson, and Totowa.
Green initiatives[edit]
In 2011, JTCC at HUMC opened a $130-million, 155,000-sq. ft. facility.[1] The JTCC pavilion was built with a green roof, providing patients and visitors with a relaxing environment[16] and doubling as exterior insulation—greatly reducing heat gain and loss.[17] This reduces energy use for heating and cooling as well as harmful emissions.[18]
Notable accomplishments[edit]
- JTCC initiated the first CAR T-cell therapy clinical trials through its NCI collaboration and became the first certified center in New Jersey to offer this treatment, in which a patient's own immune cells (T-cells) are trained to fight cancer.[19]
- JTCC supports the Northeast's largest bone marrow transplant (BMT) program and, in 2014, performed 400 transplants.[8]
- Treated first US patient with an investigatory drug for relapsed glioblastoma and other anaplastic gliomas.[20][21]
- First to use a biomarker surveillance program that screens patients who are at high-risk for developing pancreatic cancer.[22]
- Among the first of limited U.S. sites approved to offer Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded or relapsed after at least two other kinds of treatment.[23] As of 2023, it is also approved for all six commercially available CAR-T products for lymphoma, multiple myeloma and pediatric B-Cell precursor acute lymphoblastic leukemia: Yescarta, Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Abecma (idecabtagene vicleucel), and Kymriah (tisagenlecleucel).
References[edit]
- ^ a b "Hackensack Meridian John Theurer Cancer Center". Retrieved 2022-03-26.
- ^ "Hackensack, NJ". Regional Cancer Care Associates. Retrieved 2022-11-17.
- ^ Goy, Andre (2022-11-14). "Andre H. Goy, MD, on Unresolved Questions in Mantle Cell Lymphoma". Oncology. 36 (11): 651–653.
- ^ "Dr Andre Goy on Predictive Biomarker Use for CAR T-Cell Therapy Response in Patients With Large B-Cell Lymphoma". AJMC. 12 December 2021. Retrieved 2022-02-22.
- ^ "Andre Goy, MD, Appointed Physician-in-Chief to Lead Cancer Care Across Hackensack Meridian Health Network". OncLive. 18 June 2020. Retrieved 2023-04-11.
- ^ "NCI approves Georgetown-Hackensack consortium". The Cancer Letter. 2019-05-10. Retrieved 2021-08-27.
- ^ Vecchione, Anthony (2019-05-07). "NCI approves John Theurer Cancer Center as research consortium member". NJBIZ. Retrieved 2021-08-27.
- ^ a b "NCI Approves John Theurer Cancer Center as Member of Research Consortium - The ASCO Post". ascopost.com. Retrieved 2021-08-27.
- ^ Washburn, Lindy. "New cancer treatment options in Passaic County from health system partnership". North Jersey Media Group. Retrieved 2023-02-22.
- ^ "Georgetown Lombardi Comprehensive Cancer Center - NCI". www.cancer.gov. 2012-07-26. Retrieved 2023-03-22.
- ^ "Small numbers of cells in a tumor could be key enablers of cancer metastasis". EurekAlert!. Retrieved 2022-02-22.
- ^ "St. Joseph's Health and Hackensack Meridian Health: Affiliation Brings More Advanced Cancer Care To Northern New Jersey". TAPinto. Retrieved 2023-03-04.
- ^ a b "Hackensack Meridian Health John Theurer Cancer Center (JTCC) creates affiliation with Regional Cancer Care Associates (RCCA) in Toms River, NJ". Shore News Network. 2021-03-30. Retrieved 2023-04-13.
- ^ Ebenau, Vin (3 May 2022). "Jersey Shore University Medical Center now has expansive cancer care center with easier access for Ocean and Monmouth residents". 92.7 WOBM. Retrieved 2023-04-11.
- ^ "Memorial Sloan Kettering and Hackensack Meridian Health". Sloan Kettering. Retrieved November 17, 2022.
- ^ "Psychological Benefit of Green Roofs" (PDF). Ohio.edu. Retrieved March 21, 2023.
- ^ "Does a green roof have an insulating effect? - Sempergreen". www.sempergreen.com. Retrieved 2023-03-21.
- ^ "John Theurer Cancer Center at the Hackensack University Medical Center - Greenroofs.com". Greenroofs.com. Retrieved 2022-11-17.
- ^ "John Theurer Cancer Center Recognized by US News & World Report". New Jersey Business Magazine. Retrieved 2023-04-13.
- ^ Lindner, Linda (2022-03-29). "John Theurer Cancer Center treats 1st patient in U.S. with investigational drug for brain cancer". ROI-NJ. Retrieved 2022-11-17.
- ^ Tiek, Deanna M.; Erdogdu, Beril; Razaghi, Roham; Jin, Lu; Sadowski, Norah; Alamillo-Ferrer, Carla; Hogg, J. Robert; Haddad, Bassem R.; Drewry, David H.; Wells, Carrow I.; Pickett, Julie E.; Song, Xiao; Goenka, Anshika; Hu, Bo; Goldlust, Samuel A. (2022-06-24). "Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas". Science Advances. 8 (25): eabn3471. Bibcode:2022SciA....8N3471T. doi:10.1126/sciadv.abn3471. ISSN 2375-2548. PMC 9216507. PMID 35731869.
- ^ NJBIZ (2022-04-28). "Hackensack UMC unveils new pancreatic cancer test". NJBIZ. Retrieved 2022-11-17.
- ^ "John Theurer Cancer Center First NJ Site Certified to offer CAR-T Cell Cancer Therapy". OncLive. 9 March 2018. Retrieved 2022-11-17.